Other end points
tumors
TUMORS
The amount of TDM-621 applied was 1.75 ± 2.14 mL according to the operator's determination, and the operability was evaluated as “appropriately applied to the target site” in 85 patients (98.8%), all but 1. All targeted tumors were successfully removed 